Endometrial carcinoma · line 1 · Pembrolizumab + carbo + paclitaxel (endometrial advanced 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMBRO-CARBO-PACLI-ENDOM |
| ID | IND-ENDOMETRIAL-ADVANCED-1L-PEMBRO-CHEMO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-ESMO-ENDOMETRIAL-2022 SRC-GY018-MAKKER-2022 SRC-NCCN-UTERINE-2025 |
Notes
NRG-GY018/KEYNOTE-868 (PMID 35737499): pembro+carbo-pacli q3w ×6, then pembro maintenance q6w up to 35 cycles. dMMR PFS HR 0.30, pMMR HR 0.54. Choice between pembro vs dostarlimab+chemo: similar efficacy in dMMR (both HR ~0.30); access and institutional preference determine choice. pMMR patients also benefit from pembro+chemo (HR 0.54 GY018 vs HR 0.76 RUBY) — pembro+chemo preferred for pMMR. NRG-GY018 + RUBY together established the chemoimmuno paradigm across all endometrial.
Used By
Algorithms
ALGO-ENDOMETRIAL-ADVANCED-1L- ALGO-ENDOMETRIAL-ADVANCED-1L